C4 Therapeutics (CCCC) Change in Account Payables (2019 - 2026)
C4 Therapeutics' quarterly Change in Account Payables came in at -$85000.0 in Q1 2026, up 86.82% year-on-year from -$45497.9 in Q1 2025, and up 81.99% quarter-over-quarter from -$472000.0 in Q4 2025.
C4 Therapeutics has reported Change in Account Payables for 8 years, with the latest figure at -$85000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables rose 86.82% year-over-year to -$85000.0; the trailing twelve-month figure through Mar 2026 stood at $92000.0 (up 109.73% YoY), and the FY2025 full-year result was -$468000.0, down 293.28% from the prior year.
- Change in Account Payables for Q1 2026 stood at -$85000.0, up from -$472000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $1.5 million in Q2 2025, with the low at -$1.7 million in Q3 2022.
- Average Change in Account Payables over 5 years is -$219529.4, with a median of -$176000.0 recorded in 2024.
- Peak annual rise in Change in Account Payables reached 314.55% in 2025, while the deepest fall reached 454.4% in 2025.
- Tracing CCCC's Change in Account Payables over 5 years: stood at -$1.1 million in 2022, then soared by 115.71% to $169000.0 in 2023, then tumbled by 204.14% to -$176000.0 in 2024, then sank by 168.18% to -$472000.0 in 2025, then soared by 81.99% to -$85000.0 in 2026.
- The last three Change in Account Payables figures came in at -$85000.0 (Q1 2026), -$472000.0 (Q4 2025), and -$885000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -3.26 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 35.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | C4 Therapeutics | 561.03 Mn | 325.36 Mn | - | -85,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -85,000.00 |
| Mar 31, 2026 | -85,000.00 |
| Dec 31, 2025 | -472,000.00 |
| Dec 31, 2025 | -472,000.00 |
| Sep 30, 2025 | -885,000.00 |
| Sep 30, 2025 | -885,000.00 |
| Jun 30, 2025 | 1.53 Mn |
| Jun 30, 2025 | 1.53 Mn |
| Mar 31, 2025 | -645,000.00 |
| Mar 31, 2025 | -645,000.00 |
| Dec 31, 2024 | -176,000.00 |
| Dec 31, 2024 | -176,000.00 |
| Sep 30, 2024 | 590,000.00 |
| Sep 30, 2024 | 590,000.00 |
| Jun 30, 2024 | -715,000.00 |
| Jun 30, 2024 | -715,000.00 |
| Mar 31, 2024 | 182,000.00 |
| Mar 31, 2024 | 182,000.00 |
| Dec 31, 2023 | 169,000.00 |
| Dec 31, 2023 | 169,000.00 |
| Sep 30, 2023 | -837,000.00 |
| Sep 30, 2023 | -837,000.00 |
| Jun 30, 2023 | 1.08 Mn |
| Jun 30, 2023 | 1.08 Mn |
| Mar 31, 2023 | -138,000.00 |
| Mar 31, 2023 | -138,000.00 |
| Dec 31, 2022 | -1.08 Mn |
| Dec 31, 2022 | -1.08 Mn |
| Sep 30, 2022 | -1.69 Mn |
| Sep 30, 2022 | -1.69 Mn |
| Jun 30, 2022 | 588,000.00 |
| Jun 30, 2022 | 588,000.00 |
| Mar 31, 2022 | -1.15 Mn |
| Mar 31, 2022 | -1.15 Mn |
| Dec 31, 2021 | 760,000.00 |
| Dec 31, 2021 | 760,000.00 |
| Sep 30, 2021 | -601,000.00 |
| Sep 30, 2021 | -601,000.00 |
| Jun 30, 2021 | 627,000.00 |
| Jun 30, 2021 | 627,000.00 |
| Mar 31, 2021 | -1.97 Mn |
| Mar 31, 2021 | -1.97 Mn |
| Dec 31, 2020 | 600,000.00 |
| Dec 31, 2020 | 600,000.00 |
| Sep 30, 2020 | -595,000.00 |
| Sep 30, 2020 | -595,000.00 |
| Jun 30, 2020 | 2.56 Mn |
| Jun 30, 2020 | 2.56 Mn |
| Mar 31, 2020 | -2.10 Mn |
| Mar 31, 2020 | -2.10 Mn |
| Dec 31, 2019 | 1.16 Mn |
| Dec 31, 2019 | 1.16 Mn |